PEB
09/03/2016 10:02
GENERAL
NOT PRICE SENSITIVE
REL: 1002 HRS Pacific Edge Limited
GENERAL: PEB: PEB enters commercial agreement with Canterbury DHB
9 March 2016
PACIFIC EDGE ENTERS COMMERCIAL AGREEMENT WITH CANTERBURY DISTRICT HEALTH
BOARD
World-first as Cxbladder moves to replace cytology in clinical guidelines
Cancer diagnostics company, Pacific Edge Limited (NZX:PEB) has entered into a
commercial agreement to provide its innovative Cxbladder diagnostic
technology to the Canterbury District Health Board (CDHB) for primary care
referral in the evaluation of haematuria. Haematuria (blood in the urine) is
a key indicator of bladder cancer and established clinical guidelines are
that all patients with haematuria receive a urological assessment to
establish the cause. The 12 month agreement will, after an initial 200 tests,
see the replacement of cytology in Canterbury's HealthPathway for patients
with haematuria being assessed for the possibility of bladder cancer.
GM Planning and Funding at the Canterbury DHB, Carolyn Gullery said:
"Canterbury District Health Board will use the Cxbladder technology in its
new haematuria HealthPathway. The Cxbladder test performance will be audited
at the conclusion of an initial 200 tests. The expected successful perfomance
will see Cxbladder formally replace cytology on the Canterbury DHB's
HealthPathways making it available through GPs to the thousands of patients
cared for in the Canterbury region.
"We believe that Cxbladder will help support our our strategy for delivering
more care in the community closer to where people live. It also has the
potential to lower overall costs in evaluating haematuria and the detection
of bladder cancer. The Canterbury DHB has a track record of deploying
innovative and progressive clinical solutions, and we are delighted to offer
this high performance New Zealand technology from Pacific Edge."
The Canterbury HealthPathways are the main source of assessment, management
and referral information about Canterbury health services for community
healthcare providers, and are used by 80% of general practitioners more than
six times per week.
Dr Peter Davidson of Urology Associates said: "Urology Associates has been
involved in the evaluation of the Cxbladder products for some time and, we
enthusiastically support the adoption of Cxbladder Triage for use in our
clinical practice."
An arrangement with the Canterbury integrated laboratory services will will
see Cxbladder sampling systems readily available to the region's healthcare
providers through an extensive network of laboratory collection centres
(Canterbury SCL and Canterbury Health Laboratories) and general practices
throughout the region. Samples will be sent to Pacific Edge's Dunedin
laboratory for analysis and fast turn-around of test results.
CEO of Pacific Edge, David Darling, commented: "We have a long working
relationship with both Canterbury District Health Board and Urology
Associates and are delighted to be working with them to enable ready access
to Cxbladder for patients in the South Island. This is a comprehensive
process involving the whole healthcare community and represents a first for
Pacific Edge in the formal provision of Cxbladder technology to replace
cytology."
ENDS
For more information contact:
David Darling - Chief Executive Officer, Pacific Edge Ltd
P: +64 (3) 479 5800
OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer
diagnostic company specialising in the discovery and commercialisation of
diagnostic and prognostic tests for better detection and management of
cancer. The company is developing and commercialising its range of Cxbladder
bladder cancer tests globally through its wholly owned central laboratories
in New Zealand and the USA. The company's products have been tested and
validated in international multi-centre clinical studies. Pacific Edge has
two proprietary, novel, accurate, molecular diagnostic products in-market
providing actionable results, and better detection and management of
urothelial cancer. Cxbladder Detect is available through the company's
dedicated CLIA certified laboratories for customers in New Zealand, Australia
and the USA. Cxbladder Triage is available in New Zealand and Australia.
Cxbladder Monitor launched in New Zealand in December 2015 and is anticipated
being available in the US in 2016.
ABOUT Cxbladder Triage www.cxbladder.com
Cxbladder Triage combines the power of the genomic biomarkers with additional
phenotypic and clinical risk factors to accurately identify patients with
haematuria who have a low probability of bladder cancer and may not require a
more extensive urological evaluation. Cxbladder Triage is a tool for use by
clinicians and physicians in primary evaluation of patients with hematuria
and is intended to reduce the need for an expensive and invasive work-up in
patients who have a low probability of having urothelial carcinoma.
ABOUT Cxbladder Detect www.cxbladder.com
Cxbladder Detect enables the non-invasive detection of bladder and other
urinary tract cancers from a small volume of a patients' urine. Cxbladder
Detect was launched in 2013 in the USA and is commercially available in New
Zealand, Australia and the USA as a Laboratory Developed Test (LDT) from the
company's CLIA certified laboratories. Cxbladder Detect provides physicians
and clinicians with a quick, cost effective and accurate measure of the
presence of the cancer as an effective adjunct to cystoscopy.
ABOUT Cxbladder Monitor www.cxbladder.com
Cxbladder Monitor, the third test in the Cxbladder portfolio for urologists,
is a proprietary, non-invasive, molecular diagnostic test that combines
genomic biomarkers measured from a small quantity of a patient's urine, with
patient specific clinical factors to better monitor bladder cancer patients
for recurrence. Bladder cancer has a recurrence rate of 50-80% and requires
life-long surveillance. Cxbladder Monitor accurately identifies patients with
a prior history of urothelial cancer (UC) whose Cxbladder Monitor score shows
that they have a low probability of recurrent urothelial carcinoma. Cxbladder
Monitor is designed to be used as the preferred adjunct test to cystoscopy in
the management of patients for ongoing evaluation of recurrent bladder
cancer.
Refer to www.cxbladder.com for more information.
End CA:00279007 For:PEB Type:GENERAL Time:2016-03-09 10:02:43
